2016年（平成28年）

原著論文－英文

1. Trinks J, Nishida N, Hulaniuk ML, Caputo M, Tsuchiura T, Marciano S, Haddad L, Blejer J, Bartoli S, Ameigeiras B, Frías SE, Vistarini C, Heinrich F, Remondegui C, Ceballos S, Echenique G, Charre Samman M, D'Amico C, Rojas A, Martínez A, Ridruejo E, Fernández RJ, Burgos Pratx L, Salamone H, Nuñez F, Galdame O, Gadano A, Corach D, Sugiyama M, Flichman D, Tokunaga K, Mizokami M.
   Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population.
   Liver Int. Mar 7, 2017.
2. Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura YI, Dohi T, Shuno Y, Yano H, Mizokami M.
   Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
   Gut. Oct 27, 2016.
3. Adachi E, Sugiyama M, Shimizu S, Kodama K, Kikuchi T, Koga M, Mizokami M, Koibuchi T.
   Human immunodeficiency virus and hepatitis B genotype G/A2 recombinant co-infection: a case study.
   Springerplus. 5(1):1502, Sep 7, 2016.
4. Younossi Z, Stepanova M, Omata M, Mizokami M, Walters M, Hunt S.
   Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials.
   Health Qual Life Outcomes. 15(1):25, Jan 31, 2017.
5. Nishitsuji H, Ujino S, Yoshio S, Sugiyama M, Mizokami M, Kanto T, Shimotohno K.
   ong noncoding RNA #32 contributes to antiviral responses by controlling interferon-stimulated gene expression.
   Proc Natl Acad Sci U S A. 113(37):10388-93, Sep 13, 2016.
6. Nishida N, Ohashi J, Khor SS, Sugiyama M, Tsuchiura T, Sawai H, Hino K, Honda M, Kaneko S, Yatsuhashi H, Yokosuka O, Koike K, Kurosaki M, Izumi N, Korenaga M, Kang JH, Tanaka E, Taketomi A, Eguchi Y, Sakamoto N, Yamamoto K, Tamori A, Sakaida I, Hige S, Itoh Y, Mochida S, Mita E, Takikawa Y, Ide T, Hiasa Y, Kojima H, Yamamoto K, Nakamura M, Saji H, Sasazuki T, Kanto T, Tokunaga K, Mizokami M.
   Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis.
   Sci Rep. 6:24767, Apr 19, 2016.
7. Miyadera H, Ozeki T, Mushiroda T, Hirayama N.
   In silico analysis of interactions between HLA-A*31:01 and carbamazepine-related compounds.
   Chem-Bio Informatics Journal. 2016.16: 5-8.
8. Li Q, Bu W, Gabriel E, Aguilar F, Hoshino Y, Miyadera H, Hess C, Hornung RL, Roy A, Cohen, JI.
   HLA-DQ β1 alleles associated with Epstein-Barr virus (EBV) infectivity and EBV gp42 binding to cells.
   JCI Insight. 2017.2(4):e85687.
9. Nishitsuji H, Yamamoto H, Shiina R, Harada K, Ujino S, Shimotohno K.
   Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle.
   J Vi. Exp. 120:e54849, doi:10.3791/54849, 2017.
10. Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Miyoshi M Tsunoda T, Nitta S, Asano Y, Nagata H, Otani S, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S Nakauchi H, Nishitsuji H, Ujino S, Shimotohno K, Iwamoto M, Watashi K, Wakita T, Watanabe M.
    Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus.
    Sci Rep. 8;6:29358, 2016.
11. Nagao Y, Nishida N, Toyo-Oka L, Kawaguchi A, Amoroso A, Carrozzo M, Sata M, Mizokami M, Tokunaga K, Tanaka Y.
    Genome-Wide Association Study Identifies Risk Variants for Lichen Planus in Patients with Hepatitis C Virus Infection.
    Clin Gastroenterol Hepatol. Jan 5, 2017. pii: S1542-3565(17)30003-4.
12. Matsunami K, Nishida N, Kaneko N, Ikeo K, Toyo-Oka L, Takeuchi H, Matsuura K, Tamori A, Nomura H, Yoshiji H, Imamura M, Masaki N, Hayakawa T, Ide T, Shimada N, Ikeda F, Hino K, Nishiguchi S, Okuse C, Nojiri S, Sawamoto K, Tokunaga K, Joh T, Tanaka Y.
    Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C.
    PLoS One. 11(10): e0164418, 2016.
13. Kawashima M, Hitomi Y, Aiba Y, Nishida N, Kojima K, Kawai Y, Nakamura H, Tanaka A, Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Abe M, Nakao K, Yamagiwa S, Kaneko S, Honda M, Umemura T, Ichida T, Seike M, Sakisaka S, Harada M, Yokosuka O, Ueno Y, Senju M, Kanda T, Shibata H, Himoto T, Murata K, Miyake Y, Ebinuma H, Taniai M, Joshita S, Nikami T, Ota H, Kouno H, Kouno H, Nakamuta M, Fukushima N, Kohjima M, Komatsu T, Komeda T, Ohara Y, Muro T, Yamashita T, Yoshizawa K, Nakamura Y, Shimada M, Hirashima N, Sugi K, Ario K, Takesaki E, Naganuma A, Mano H, Yamashita H, Matsushita K, Yamauchi K, Makita F, Nishimura H, Furuta K, Takahashi N, Kikuchi M, Masaki N, Tanaka T, Tamura S, Mori A, Yagi S, Shirabe K, Komori A, Migita K, Ito M, Nagaoka S, Abiru S, Yatsuhashi H, Yasunami M, Shimoda S, Harada K, Egawa H, Maehara Y, Uemoto S, Kokudo N, Takikawa H, Ishibashi H, Chayama K, Mizokami M, Nagasaki M, Tokunaga K, Nakamura M.
    Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population.
    Hum Mol Genet. 26(3):650-659, 2017.

原著論文－和文

1. 宮寺 浩子.
   1型糖尿病とHLAの低安定性.
   細胞. 636:255-260, 2016.
2. 宮寺 浩子, 野口 恵美子, 溝上 雅史, 徳永 勝士.
   HLAクラスII結合ペプチドの探索・同定法の開発.
   臨床免疫学会会誌. 40(1):35-39, 2017.

口頭・ポスター発表－国際学会・研究会

1. Mizokami M.
   Clinical data of Innovative DAA drugs in Asian HCV patients.
   Chinese Liver Management & Fibrosis Forum. 北京, May 28, 2016.
2. Mizokami M.
   HCV Epidemiology and Disease Burden.
   APASL Single Topic Conference on HCV. Post Graduate 1-1, 高雄, Jun 10, 2016.
3. Mizokami M.
   Global Burdens and Survey of Hepatitis C in Different Regions of the World.
   APASL Single Topic Conference on HCV. Plenary Session 1-1, 高雄, Jun 10, 2016.
4. Mizokami M.
   Real-World Data from Asia-Pacific. The Power of SOF: Moving Towards CHC Eradication.
   APASL Single Topic Conference on HCV. Post Graduate 1-1, 高雄, Jun 11, 2016.
5. Mizokami M, Nishida N, Tokunaga K.
   Associations between HLA class II genes and chronic hepatitis B infection in the Japanese population.
   2016 International HBV Meeting. Seoul, Sep 21-24, 2016.
6. Mizokami M.
   What is M2BPGi and It’s Clinical Utility in Liver Diseases?
   APDW2016 Evening Seminar 2. Kobe, Nov 3, 2016.
7. Mizokami M.
   Molecular Evolutionary Analysis of Hepatitis C Virus: Its Application to HCV and Host Genome.
   KAUSAT Research Conference: Computational Systems Biology in Biomedicine. Jeddah, Saudi Arabia, Dec 6, 2016.
8. Mizokami M.
   What is M2BPGi? - Is M2BPGi Useful in Clinics? -.
   M2BPGi Opinion Leader Meeting. Seoul, Feb 15, 2017.
9. Lai Wei, Masao Omata, Young-Suk Lim, Wan-Long Chuang, Dao Long, Xie Qing, Jin Lin Hou, Jidong Jia, Evguenia Svarovskaia, Ross Martin, Brian Doehle, Jenny Hang, Shampa De-Oertel, Benedetta Massetto, Kathryn Kersey, Diana M, Braianard, Hongmei Mo, Nguyen Kinh, Jia-Horng Kao, Kwang-Hyub Han, Mizokami M, Zhongping Duan.
   Prevalence of Pretereatment NS5A and NS5B NI-Resistance Associated Substitutions in HCV-Infected Patients Enrolled in Clinical Trials in Asia.
   APASL 2017 Shanghai, 上海, Feb 17, 2017
10. Mizokami M.
    Detection and Impact of Resistance Associated Variants.
    APASL 2017 Shanghai, 上海, Feb 18, 2017
11. Suekuni K, Sugiyama M, Kanto T, Mizokami M.
    First year report of Kohnodai Hospital Biobank: Construction of Biobank-coordinator workflow.
    The 13th International Congress of Human Genetics. Poster P-319, Kyoto, Apr 6, 2016.
12. Sugiyama M, Kanto T, Mizokami M.
    Toll-like receptor 4 pathway mediate liver fibrosis in chimeric mice with human hepatocytes persistently infected with HBV.
    The international Liver Congress 2016 EASL. Poster P-196, Barcelona, Apr 14, 2016.
13. Sugiyama M, Kanto T, Mizokami M.
    Toll-like receptor 4 pathway mediate liver fibrosis in chimeric mice with human hepatocytes persistently infected with HBV.
    The international Liver Congress 2016 EASL. Oral ePoster Booth1-4, Barcelona, April 16, 2016.
14. Miyadera H, Ohashi J, Tokunaga K.
    Stability profiling of HLA class II protein for disease association studies.
    The 13th International Congress of Human Genetics. Kyoto, Apr 3-7, 2016.
15. Miyadera H, Okabe Y, Cindy Chia-Jung Chen, Tokunaga K, Mizokami M.
    A large scale screening of HLA-class II-binding peptides from HBs and HBc peptide libraries.
    The American Association of Immunologist (AAI) annual meeting. Seattle, USA, May 13-17, 2016.
16. Miyadera H, Ohashi J, Tokunaga K.
    HLA class II protein stability and disease susceptibility.
    16th International Congress of Immunology. Melbourne, Australia, Aug 21-26, 2016.
17. Miyadera H, Okabe Y, Cindy Chia-Jung Chen, Tokunaga K, Mizokami M.
    Large scale analysis of HLA-peptide interactions.
    66th Annual Meeting of the American Society of Human Genetics. Vancouver, Canada. Oct 18-22, 2016.
18. Nishida N, Ohashi J, Sugiyama M, Tsuchiura T, Ishii M, Tokunaga K, Mizokami M.
    Effects of HLA-DPB1 genotypes on HBV-related diseases in Japanese population.
    The 13th International Congress of Human Genetics. Kyoto, Apr 3-7, 2016.
19. Nishida N, Ohashi J, Khor SS, Sugiyama M, Sawai H, Tokunaga K, Mizokami M.
    Comprehensive understanding of associations between HLA class II genes and chronic hepatitis B infection in Japanese individuals.
    66th Annual Meeting of the American Society of Human Genetics. Vancouver, Canada. Oct 18-22, 2016.
20. Nishida N, Ohashi J, Sugiyama M, Sawai H, Hino K, Honda M, Kaneko S, Yatsuhashi H, Yokosuka O, Koike K, Kurosaki M, Izumi N, Korenaga M, Kang Jong-Hon, Tanaka E, Taketomi A, Eguchi Y, Sakamoto N, Yamamoto K, Tamori A, Sakaida I, Hige S, Itoh Y, Mochida S, Mita E, Takikawa Y, Ide T, Hiasa Y, Nakamura M, Saji H, Sasazuki T, Kanto T, Tokunaga K, Mizokami M.
    Comprehensive understanding of associations between HLA class II genes and chronic hepatitis B infection in the Japanese population.
    American Association for the study of Liver Diseases The Liver Meeting 2016. Boston, Nov 11-15, 2016.
21. Date T, Aihara N, Watanabe N, Aizaki H, Sugiyama M, Mizokami M, Delaney W Ⅳ, Cheng G, Wakita T.
    Infectious Genotype 4a Hepatitis C Virus in Cell Culture 2016.
    APASL Single Topic Conference on Hepatitis C Kaohsiung Exhibition Center, Kaohsiung, Taiwan, Jun 10-12, 2016.
22. Date T, Sugiyama M, Lkhagvasuren D, Oyunsuren T, Wakita T, Mizokami M.
    Prevalence of non-primate heapcivirus in horse in Mongolia.
    23rd International Symposium on Hepatitis C Virus and Related Viruses Kyoto, Japan, Oct 11-15, 2016.
23. Nishida N, Ohashi J, Sugiyama M, Tsuchiura T, Ishii M, Tokunaga K, and Mizokami M. Effects of HLA-DPB1 genotypes on HBV-related diseases in Japanese population.
    The 13th International Congress of Human Genetics. Poster P-60, Kyoto, Apr 5, 2016.
24. Sawai H, Nishida N, Sugiyama M, Khor S, Mizokami M, and Tokunaga K.
    Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma.
    The 13th International Congress of Human Genetics. Kyoto, April 5th, 2016 Poster P-75
25. Nisihda N, Sugiyama M, Tokunaga K, Mizokami M.
    HLA genotypes and disease susceptibility.
    APASL2017; New Direction of Genetics in Liver Diseases. 上海, Feb 17, 2017.
26. Ujino S, Nishitsuji H, Shimotohno K.
    CD81-independent HCV entry utilizing very-low-density lipoprotein.
    23rd International Symposium on Hepatitis C Virus and Related Viruses. Kyoto, Japan, Oct, 2016.
27. Nishitsuji H, Ujino S, Shimotohno K.
    Long non-coding RNA #32 confers to antiviral responses by controlling.
    23rd International Symposium on Hepatitis C Virus and Related Viruses. Kyoto, Japan, Oct, 2016.

口頭・ポスター発表－国内学会・研究会

1. 溝上 雅史.
   B型肝炎研究のUp-To-Date.
   第52回日本肝臓学会総会. 特別発言シンポジウム1, 千葉, 5月, 2016.
2. 溝上 雅史.
   現在のHBワクチンは本当にHBV感染を防ぐのか？
   第1回宮川庚子記念研究財団研修会. 東京, 9月, 2016.
3. 溝上 雅史.
   臨床現場でのC型肝炎治療~治験と比較して~.
   佐賀県医師会学術講演会. 佐賀, 12月, 2016.
4. 溝上 雅史.
   What and How do IFNλ in Hepatitis Virus Infection? ~B型肝炎への応用を含めて~.
   北海道大学. 札幌, 10月, 2016.
5. 溝上 雅史.
   臨床現場でのC型肝炎治療~治験と比較して~.
   蒼もろ肝炎フォーラム. 青森, 11月, 2016.
6. Mizokami M, Wan-Long Chuang, Kwang-Hyub Han, Young-Suk Lim, Jenny C. Yang, Shampa De-Oertel, Macky Natha, Bing Gao, Hongmei Mo, Phillip S. Pang, Steven J. Knox, John G. McHutchison, Masao Omata, Jia-Horng Kao.
   Asian Genotype 1 HCV Achieve 99% SVR With 12 Weeks of Ledipasvir/Sofosbuvir: Integrated Analysis of Phase 3 Multicenter Studies.
   第52回日本肝臓学会総会. 千葉, 5月, 2016.
7. 杉山真也, 考藤 達哉, 溝上 雅史.
   TLR4経路阻害によるB型肝炎ウイルス感染キメラマウスの肝線維化抑制効果の検討.
   第52回日本肝臓学会総会. ワークショップWS4-8, 千葉, 5月, 2016
8. Masaya Sugiyama, Tatsuya Kanto, Masashi Mizokami.
   TLR4 signaling mediates liver fibrosis in chimeric mice with humanized liver persistently infected with HBV特別企画JSH-EASL Joint Meeting.
   第52回日本肝臓学会総会. SP1-2, 千葉, 5月, 2016.
9. Masaya Sugiyama, Nao Nishida, Katsushi Tokunaga, Masashi Mizokami.
   Variation of PreS-S gene in HBV-associated HCC patients with HLA-DPB1*0201.
   第64回日本ウイルス学会学術集会. ポスターP1-092, 札幌, 10月, 2016.
10. 宮寺 浩子, 岡部 由紀, Cindy Chia-Jung Chen, 徳永 勝士, 溝上 雅史.
    HLA-DP提示HBs、HBc抗原領域の探索.
    第52回日本肝臓学会総会. 千葉. 5月, 2016.
11. 宮寺 浩子, 徳永 勝士, 野口 恵美子.
    HLA結合ペプチドの大規模探索法の開発.
    第44回日本臨床免疫学会総会. 東京, 9月, 2016.
12. 宮寺 浩子, 岡部 由紀, Cindy Chia-Jung Chen, 徳永 勝士, 溝上 雅史.
    HLAクラスII提示B型肝炎ウイルス抗原領域の探索.
    第25回日本組織適合性学会大会. 札幌. 10月, 2016.
13. 西田 奈央.
    肝疾患研究におけるゲノム解析.
    2016年度 大学共同利用機関法人 情報・システム研究機構 国立遺伝学研究所 研究会. 静岡, 6月, 2016.
14. 西田 奈央.
    自己免疫性肝疾患の遺伝的背景.
    School of AutoImmune Liver Disease. 幕張, 2017.1.7-8.
15. 西田 奈央, 杉山 真也, 澤井 裕美, 考藤 達哉, 徳永 勝士, 溝上 雅史.
    HBV関連疾患とHLAの関連.
    第52回日本肝臓学会総会. 幕張, 5月, 2016.
16. 西田 奈央, 澤井 裕美, 大橋 順, Seik-Soon Khor, 杉山 真也, 土浦 貴代, 石井 真由美, 徳永 勝士, 溝上 雅史.
    日本人におけるB型肝炎関連疾患とHLA遺伝子の関連.
    第39回日本分子生物学会. 横浜, 11月, 2016.

著書・総説

その他